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Abstract
Background Anecdotal evidence suggests that metformin
titration instructions are not being updated and refill re-
quests are approved without modification of the titration
instructions such that the titration instructions is continued
for patients newly initiated on metformin.
Methods This was a retrospective cohort analysis of adult
patients who received newly initiated metformin pharma-
cotherapy. Patients were followed from their initial met-
formin purchase through two subsequent metformin refill
purchases. Outcomes, including the 3-year incidence rate
of patients with at least one set of continued titration in-
structions and proportions of patients with at least one
gastrointestinal adverse effect (AE) and those with an
elevated glucose measurement at follow-up, were assessed
during the time period between patients’ second and third
metformin purchases. Analyses were performed comparing
the exposure (i.e., patients with continued instructions)
group to the control (i.e., patients without continued in-
structions) group.
Results The exposure group had a higher mean age and
chronic disease score but lower metformin starting dose
than the control group (all p\ 0.05). The 3-year incidence
rate of patients with at least one continuation of titration
instructions was 60.3 % (95 % CI 58.3–62.3). Gastroin-
testinal AEs were rare with equivalent proportions of pa-
tients in each group experiencing an event (p[ 0.05).
Control patients (48.7 % of patients with a measurement)
were more likely to have had poorly controlled glucose
than exposure patients (35.7 % of patients with a mea-
surement) (p\ 0.001).
Conclusions A high rate of continuation of titration in-
structions for patients newly initiated on metformin was
observed; however, such continuation did not negatively
affect clinical outcomes.
Key Points
Anecdotal evidence suggests that metformin titration
instructions are not being updated and refill requests
are approved without modification of the titration
instructions such that the titration instruction is
continued for patients newly initiated on metformin.
We found a high rate of patients with at least one
titration instruction continuation (3-year incident
rate = 60.3 % [95 % CI 58.3–62.3]); however, such
continuation did not negatively affect clinical
outcomes.
Our analysis highlights a potential risk of electronic
prescribing and likely patient non-adherence to
directions printed on prescription labels.
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1 Background
The prevalence of type 2 diabetes mellitus (DM) con-
tinues to increase [1]. Metformin (Glucophage), an
oral biguanide, is first-line pharmacotherapy for the
management of type 2 DM and is one of the most
widely prescribed medications overall [2]. While met-
formin is effective, its adverse effects (AEs) include
gastrointestinal disorders, which can lead to poor ad-
herence and, subsequently, reduced glycemic control
[3]. Upward dose titration is recommended when met-
formin therapy is initiated to decrease the potential for
AEs and identify the minimum dose for adequate gly-
cemic control [4]. For example, a patient’s initial
metformin prescription can have instructions that direct
a patient to ‘‘Take one tablet by mouth twice daily for
1 week, increase to two tablets in the morning and one
tablet in the evening, and then increase to two tablets
twice daily’’. Patients often reach their target mainte-
nance dose after 1 month [2].
After completing the dose titration phase, patients
should receive a new prescription with updated instruc-
tions that reflect the maintenance dosing directions.
However, with the increased use of electronic prescribing
(e-prescribing) in the USA, there is a potential for un-
foreseen errors when providing new prescriptions [5].
Recent studies have drawn attention to some of the
concerns associated with e-prescribing. These studies
have focused on discrepancies in patient instructions that
could potentially place individuals at risk for medication
errors [6, 7].
Kaiser Permanente Colorado (KPCO) uses an elec-
tronic medical record (EMR) system for its information
management and care delivery infrastructure. The EMR
integrates inpatient, outpatient, and clinic medical
records with appointments, registration, pharmacy, and
billing information. Anecdotal evidence at KPCO sug-
gested that metformin titration instructions were not
being updated and refill requests may have been ap-
proved without modification of the titration instructions.
So, instead of updated instructions directing a patient to
take two tablets twice daily, titration instructions were
perpetuated during e-prescribing with titration direc-
tions. Re-initiating titration may leave patients suscep-
tible to decreased glycemic control but, conversely, less
likely to report an AE. Little information exists on
continued metformin titration instructions. The purpose
of this analysis was to assess the incidence rate and
effect of continued metformin titration instructions in a
population of patients being initiated on metformin
therapy.
2 Methods
2.1 Analytic Design and Setting
This was a retrospective cohort analysis of adult patients
who received newly initiated metformin pharmacotherapy
between 1 January 2011 and 31 December 2013. Patients
were followed from their initial metformin purchase
through two subsequent metformin refill purchases. Out-
comes were assessed during the time period between pa-
tients’ second and third metformin purchases, as this was
hypothesized as the time period during which the effects of
inappropriate titration were most likely to manifest [8].
This analysis was conducted at KPCO, an integrated
healthcare delivery system with over 580,000 members and
27 ambulatory care clinics in Colorado at the time of the
analysis. Kaiser Permanente Colorado utilizes an EMR that
provides e-prescribing capabilities and captures coded and
free-text medical, pharmacy, laboratory, emergency de-
partment (ED), hospitalization, membership, and death
information internally from within the health system, as
well as from other contracted and affiliated facilities.
Kaiser Permanente Colorado owns and operates its phar-
macies where its members can purchase subsidized pre-
scription medications. Information on such purchases is
captured in the electronic KPCO administrative pharmacy
database.
The proposal for this analysis was reviewed by the
KPCO Institutional Review Board and determined to not
be Human Subjects Research, as defined by federal
regulations and institutional policies, since it was con-
ducted as a quality assurance project.
2.2 Patient Population
Patients included in this analysis: (1) had purchased a new
500-mg metformin prescription at a KPCO pharmacy be-
tween 1 January 2011 and 13 December 2013; (2) were
C18 years of age on the purchase date (index date); (3) had
no metformin purchase in the 180 days prior to index date
(pre-period); (4) had at least two additional metformin
purchases in the 180 days after the initial (index) purchase;
(5) had continuous KPCO health plan membership with
pharmacy benefit during the pre-period and through the
third metformin purchase; and (6) had a type 2 DM or pre-
diabetes diagnosis (ICD-9 codes available upon request)
during the pre-period. Exposure patients (titration contin-
ued group) had titration instructions on the index purchase
with the titration instructions repeated (i.e., continued) on
at least the second metformin purchase. Control patients
(titration limited group) had titration instructions on their
188 T. Delate et al.
index purchase but the titration instructions were not con-
tinued on the second metformin purchase.
2.3 Outcomes
The primary outcome was the 3-year incidence rate (with
95 % confidence interval [CI]) of metformin prescription
purchase with titration instructions continued on the sub-
sequent metformin purchase. Secondary outcomes included
assessments of the proportion of patients with at least one
gastrointestinal AE, hyperglycemic glucose laboratory
measurement, all-cause hospitalization, ED visit, and in-
sulin/sulfonylurea purchase during follow-up.
2.4 Data Collection
The analysis cohort and patient characteristics and out-
comes were identified through queries of KPCO’s elec-
tronic administrative databases, including the EMR.
Outcomes were assessed during the time period between
patients’ second and third metformin purchases. Outcome
AEs included dyspepsia (ICD-9 code 536.8), diarrhea
(ICD-9 code 787.91), nausea (ICD-9 code 787.02), vom-
iting (ICD-9 code 787.03), and nausea and vomiting (ICD-
9 code 787.01) recorded during a telephone or medical
office visit encounter. A hyperglycemic glucose laboratory
measurement was defined as an A1c C7.0 %, a fasting
blood glucose (FBG) C126 mg/dL, or a random glucose
(RG) C200 mg/dL recorded in a medical office laboratory.
Information on co-morbidities diagnosed during tele-
phone/medical office encounters during the pre-period in-
cluded dementia, heart failure, hepatic disorders,
hypertension, polycystic ovarian disease, and renal insuf-
ficiency (ICD-9 codes available upon request). Addition-
ally, information on the index metformin provider,
metformin dose, count of unique prescription purchases
and elevated glucose measurements during the pre-period
(i.e., the 180 days prior to the index purchase) was col-
lected. Furthermore, a chronic disease score (CDS), a
validated measure of a patient’s burden of chronic illness,
was calculated using ambulatory prescription medication
purchases during the pre-period [9]. The CDS ranges from
0 to 36 with increasing values indicating a higher burden of
chronic illness.
2.5 Data Analysis
Age was calculated as of the index date. Incident rate of
titration instructions continuation was calculated by di-
viding the count of patients who purchased a new met-
formin prescription during the analysis period with
continued titration instructions by the count of all patients
with a new metformin prescription purchased during the
analysis period. The glucose measurements used were
those recorded during the pre-period and most proximal to,
but before, the index date and after the second purchase,
but before the third purchase date. Patients with no mea-
surement available were excluded from this analysis.
All analyses were performed comparing the exposure to
the control group. Patient characteristics and outcomes
were reported as means (±standard deviations [SDs]) for
interval-level variables and percentages for categorical
variables. Wilcoxon rank-sum tests and t tests, as appli-
cable, and chi-square tests of association or Fisher’s exact
tests, as applicable, were used to assess differences be-
tween groups for interval-level and categorical variables,
respectively. Multivariate logistic regression analysis was
performed for each outcome (except gastrointestinal AEs
as the incidence was too low to perform adjustments). The
titration limited group was the referent category and ad-
justment was made for all baseline patient characteristics
with a p value\0.2 in the bivariate analyses (i.e., age, sex,
pre-period elevated glucose laboratory measurement,
chronic disease score, primary-care index metformin pre-
scriber, index metformin dose, hepatic disorder, and
hypertension).
3 Results
A total of 2416 patients were included with 1457 (60.3 %)
and 959 (39.7 %) having and not having had titration in-
structions continued, respectively. The titration continua-
tion group had a higher mean age and CDS but lower mean
metformin starting dose than the titration limited group (all
p\ 0.05) (Table 1). In addition, the titration continuation
group was less likely to have been prescribed metformin by
a primary-care provider and to have had an elevated glu-
cose measurement in the pre-period but more likely to have
been diagnosed with hypertension (all p\ 0.05).
The 3-year incidence rate of patients with at least one
continuation of titration instructions was 60.3 % (95 % CI
58.3–62.3). Gastrointestinal disorder AEs, with equivalent
proportions of patients in each group experiencing an
event (p = 0.766) (Table 2). 981 (40.6 %) patients had a
glucose measurement recorded between their second and
third metformin purchases. Of these, titration-limited pa-
tients (48.7 % of patients with a measurement) were more
likely to have had a hyperglycemic glucose laboratory
measurement than titration-continuation patients (35.7 %
of patients with a measurement) (p\ 0.001). There were
no differences between groups in the proportions of pa-
tients who experienced an all-cause hospitalization or ED
visit (both p[ 0.05). Titration-limited patients were more
likely to have had an insulin/sulfonylurea purchase
(19.4 % vs. 13.0 %, p\ 0.001). In the multivariate
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adjusted analysis, titration continuation patients had a
26 % reduction in the likelihood of at least one hyper-
glycemic glucose laboratory measurement (odds ratio
[OR] 0.74, 95 % CI 0.56–0.98) and 24 % reduction in the
likelihood of an insulin/sulfonylurea purchase (OR 0.76,
95 % CI 0.60–0.97) between their second and third met-
formin purchases (Table 3).
4 Discussion
This retrospective cohort analysis is the first, to our
knowledge, to assess the effect of continuation of titration
instructions during e-prescribing in patients newly initiated
on metformin. We found that the majority ([60 %) of
patients experienced continuation of titration instructions,








Mean agea (SD) 57.3 (12.7) 58.2 (12.8) 56.0 (12.4) \0.001
Female (n, %) 1259, 52.1 % 779, 53.5 % 480, 50.1 % 0.100
Primary-care index metformin prescriber (n, %) 2129, 88.1 % 1255, 86.1 % 874, 91.1 % \0.001
Mean chronic disease score (SD) 3.2 (3.0) 3.3 (2.9) 3.1 (3.1) 0.017
Mean count of unique Rx Medications purchasedb (SD) 5.8 (4.0) 5.8 (3.9) 5.8 (4.2) 0.474
Mean index metformin dose (mg, SD) 1184 (743) 1082 (664) 1339 (850) \0.001
Pre-period elevated glucose laboratory measurementb,c (n, %) 1718, 73.7 %d 947, 67.8 %e 771, 82.5 %f \0.001
Ambulatory co-morbidity diagnosisb (n, %)
Dementia 16, 0.7 % 12, 0.8 % 4, 0.4 % 0.308
Heart failure 24, 1.0 % 14, 1.0 % 10, 1.0 % 0.843
Hepatic disorder 70, 2.9 % 49, 3.4 % 21, 2.2 % 0.093
Hypertension 823, 34.1 % 522, 35.8 % 301, 31.4 % 0.024
Polycystic ovarian disease 0, 0.0 % 0, 0.0 % 0, 0.0 % 1.000
Renal insufficiency 192, 8.0 % 121, 8.3 % 71, 7.4 % 0.423
a At the time of index metformin purchase
b During the 180 days prior to index metformin purchase
c Recorded value most proximal to, but before, the index metformin purchase, A1c C6.5 %, fasting glucose PCLAB_MQ C126 mg/dL, or
random glucose C200 mg/dL
d Percent is of the 2332 (96.5 %) patients who had at least one measurement
e Percent is of the 1397 (95.9 %) patients who had at least one measurement
f Percent is of the 935 (97.5 %) patients who had at least one measurement








Gastrointestinal adverse event (n, %) 2, 0.1 % 1, 0.1 % 1, 0.1 % 0.766
At least one hyperglycemic glucose laboratory measurementa (n, %) 405, 41.4 %b 198, 35.7 %c 207, 48.7 %d \0.001
All-cause hospitalization (n, %) 37, 1.5 % 24, 1.7 % 13, 1.4 % 0.568
All-cause emergency department visit (n, %) 97, 4.0 % 58, 4.0 % 39, 4.1 % 0.916
Insulin/sulfonylurea purchase (n, %) 375, 15.5 % 189, 13.0 % 186, 19.4 % \0.001
Recorded between the second and third metformin purchase dates
a Recorded most proximal to, but before, the third metformin purchase date, A1c C7.0 %, fasting glucose PCLAB_MQ C126 mg/dL, or random
glucose C200 mg/dL
b Percent is of the 979 (40.7 %) patients who had at least one measurement
c Percent is of the 554 (38.0 %) patients who had at least one measurement
d Percent is of the 425 (44.3 %) patients who had at least one measurement
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suggesting that, while e-prescribing may allow for quicker
and more convenient prescribing [10], such benefits can
come with unintended consequences (e.g., refill request
approvals by the prescriber without proper assessment of
prescription details) [6, 7]. Nevertheless, we found that
continuation of titration instructions did not negatively
affect clinical outcomes, as patients with continuation of
titration instructions were less likely to have had poorly
controlled glucose and no more likely to have had a gas-
trointestinal AE compared to patients without continuation
of titration instructions. The exposure group would be ex-
pected to have worse glycemic control, but fewer AEs, if
they had re-initiated their titrations as directed on their
prescription’s instructions.
The reason for the lower proportion of patients with
poorly controlled glucose in the exposure group during
follow-up is difficult to pinpoint. The control group was
initiated on a higher metformin dose, presumably to
achieve more rapid glycemic control, but had worse gly-
cemic control during the pre-period. In addition, the control
group had a numerically lower rate of renal insufficiency
such that they may have had better clearance of metformin.
Since metformin is primarily cleared renally, any insuffi-
ciency could lead to accumulation of metformin and, per-
haps, an increased risk of metformin-related AEs that
hindered glycemic control [11, 12]. Furthermore, the con-
trol group may have had more severe DM/pre-diabetes as
they were more likely to have received insulin or a sul-
fonylurea during follow-up. This is countered by the fact
that the control patients were less likely to have been
prescribed their index metformin by a specialist (e.g., an
endocrinologist). This finding suggests that specialists were
less likely to correct titration instructions for subsequent
prescription fills.
While clinicians report perceived efficiencies in pro-
cessing refills with e-prescribing [9], we identified no other
studies of continuation of titration instructions with which
to compare our findings. However, other investigators have
attempted to rectify discrepancies in components of elec-
tronic prescriptions. Turchin and colleagues [13] modified
the user interface in an EMR prescription ordering module
to provide alerts to discrepancies. Theoretically, a func-
tionality could be built into an EMR to alert prescribers to
modify titration instructions once maintenance doses of
certain medications have been achieved.
Our analysis had several limitations. We were unable to
assess if patients actually re-initiated metformin titration.
We only assessed if the titration instructions were contin-
ued. We were unable to assess if patients in the titration
continued group were told by their prescribers to continue
taking the target maintenance dose, regardless of the di-
rections printed on their prescription labels. A dispensing
pharmacist may have noticed the continuation of the ti-
tration instructions. However, the pharmacist would likely
only have counseled the patient to see if she/he was at her/
his maintenance dose and not otherwise altered the pre-
scription. We were unable to measure the severity of our
patients DM/pre-diabetes at baseline. Nevertheless, we did
assess glycemic control at baseline as a proxy. Some pa-
tients may have tried and failed metformin prior to our
180-day pre-period. But in order to achieve the largest
sample size possible, we included such patients as they
were likely to experience the same effects as truly naı¨ve
metformin users. A limited number of prescriptions could
have been initiated outside the KPCO e-prescribing system
(e.g., during an inpatient stay/emergency room visit,
transferred from a non-KPCO prescriber), but all pre-
scriptions would have been renewed with e-prescribing.
We did not assess metformin adherence such that those
patients with an elevated glucose during follow-up may
have been less adherent, regardless of the directions given.
However, patients in our analysis had to have had at least
two additional metformin purchases in the 180 days after
index purchase indicating, at least, a modest level of ad-
herence. This analysis was conducted in one health plan
where titration instructions are printed on the prescription
bottle and its results may not be generalizable to all health
plans (e.g., where titration instructions are provided











Titration continued 0.74 0.56–0.98
Titration limited Referent –
All-cause hospitalization 0.563
Titration continued 1.24 0.60–2.53




Titration continued 1.01 0.65–1.55
Titration limited Referent –
Insulin/sulfonylurea purchase 0.026
Titration continued 0.76 0.60–0.97
Titration limited Referent –
Recorded between the second and third metformin purchase dates
Adjusted for age, sex, pre-period elevated glucose laboratory mea-
surement, chronic disease score, primary-care index metformin pre-
scriber, index metformin dose, hepatic disorder, and hypertension
a Recorded most proximal to, but before, the third metformin pur-
chase date, A1c C7.0 %, fasting glucose PCLAB_MQ C126 mg/dL,
or random glucose C200 mg/dL. Analysis limited to patients with
both a pre-period and outcome glucose/A1c measurement (n = 945)
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verbally to a patient). However, we had a relatively large
cohort of patients to assess the impact of continuation of
metformin titration instructions and other health plans with
e-prescribing may find similar results.
In conclusion, we found a high rate of continuation of
titration instructions during e-prescribing for patients
newly initiated on metformin. However, such continuation
did not negatively affect clinical outcomes. Our analysis
ultimately highlights a potential risk of e-prescribing and
likely patient non-adherence to directions printed on pre-
scription labels. While an alert in an EMR to modify in-
structions may attenuate the continuation of titration
instructions, patient non-adherence to prescribers’ direc-
tions may portend serious consequences in the long term.
Future research should assess patient-reported adherence to
the directions for use on prescription labels and evaluate
ways to systematically alert prescribers to inappropriate
refilling practices.
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